Truist analyst Jailendra Singh lowered the firm’s price target on Icon (ICLR) to $295 from $363 and keeps a Buy rating on the shares. With the Q4 and 2025 outlook now essentially de-risked, Truist ...
UBS analyst David Lai lowered the firm’s price target on Perspective Therapeutics (CATX) to $7 from $18 and keeps a Buy rating on the shares. Claim 60% off TipRanks Premium for the data-backed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback